Target intelligence / Profile preview

Membrane protein MLC1 (MLC1)

Target
MLC1
Molecular classification
Membrane protein, Putative transporter/modulator, Ion channel modulator (does not directly form the VRAC channel itself, but modulates VRAC activity), Other (not a classical receptor, enzyme, transporter, or transcription factor)
01

Overview

Membrane protein MLC1 is a transmembrane protein, most highly expressed in brain astroglial cells, that fine-tunes cell junctions by regulating the strength of adhesion and possibly the transport of fluids and small molecules across the blood-brain barrier. MLC1 modulates VRAC currents, but is not a pore-forming subunit of the channel itself—instead, it acts as a regulatory accessory protein, possibly via interaction with GlialCAM and other partners. Pathogenic mutations in the gene cause most cases of megalencephalic leukoencephalopathy with subcortical cysts, a rare neurological disorder marked by macrocephaly, movement impairment, and seizures. Emerging research suggests an autoimmune role, with MLC1 as a potential antigenic target in multiple sclerosis[1][3][5][7][9].

Other names
KIAA0027LVMmegalencephalic leukoencephalopathy with subcortical cysts 1 gene productMLCMLC1_HUMANWKL1Modulator of VRAC current 1
02

Mechanism of action

For potential therapies, mechanisms would involve modulation of VRAC currents in astroglial cells, restoration of normal ion and fluid homeostasis, and possibly immune modulation. In autoimmune disease (multiple sclerosis), immune responses may target MLC1.

03

Biological functions

Regulates junctions between astroglial cellsModulates VRAC currents (volume regulation)May regulate cell adhesion or molecular transport across the blood-brain barrierMay participate in ion homeostasis
04

Disease associations

Leukodystrophy (specifically, megalencephalic leukoencephalopathy with subcortical cysts)Multiple sclerosis (identified as a target antigen, with possible relevance for autoimmunity)Other neurodegenerative or neurodevelopmental disease associations are still under investigation
05

Safety considerations

Targeting MLC1 could potentially affect brain fluid/ion balance, blood-brain barrier integrity, and neural cell adhesionOff-target immune effects have not yet been characterized
06

Interacting drugs

No approved drugs directly targeting MLC1 as of now; research is ongoing into therapeutics modulating VRAC activity or its regulation

1 more in the full profile.

07

Biomarkers

Variants or autoantibodies against MLC1 may be investigated as biomarkers for megalencephalic leukoencephalopathy and possibly multiple sclerosis

Beyond the preview

Go deeper on Membrane protein MLC1 (MLC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Membrane protein MLC1 (MLC1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call